NCT02360540

Brief Summary

PERC rule was created to rule out pulmonary embolism (PE) without further exams, with residual PE risk \<2%. Its safety is currently confirmed in low PE prevalence populations as north-American. In European high PE prevalence population, it has been showed that PERC rule used alone or associated with low clinical probability assessed by revised Geneva score (RGS) was not safe. In retrospective study, we suggest that the combination of PERC rule with implicit clinical probability (gestalt) could allow the use of the PERC rule. PERCEPIC, an observational prospective multicenter study performed in France and Belgium, will test this hypothesis. Therefore, 3000 patients will be included in 12 centers. Primary outcome will be the rate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule (8 criteria absents). Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,773

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2015

Geographic Reach
2 countries

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 10, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

September 22, 2016

Status Verified

September 1, 2016

Enrollment Period

1.2 years

First QC Date

February 5, 2015

Last Update Submit

September 21, 2016

Conditions

Keywords

Pulmonary EmbolismDiagnostic strategyExclusionClinical probabilityImplicit Judgment (Gestalt)PERC

Outcome Measures

Primary Outcomes (1)

  • To assess the accuracy of the combination of low implicit clinical probability (gestalt) and negative PERC rule (8 criteria absents)

    Rate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule. Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination

    3 months

Secondary Outcomes (3)

  • To assess usefulness of PERC and implicit low clinical probability combination to reduce the use of further exams

    During emergency managment

  • To assess the accuracy of PERC and low clinical probability combination depending of clinical probability assessment method (implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score)

    3 months

  • To compare performances of clinical probability assessment methods : implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score

    3 months

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients admitted to the emergency department for dyspnea or thoracic pain without another obvious cause or suspected PE

You may qualify if:

  • \- Patients admitted to the emergency department for one of the following criteria :
  • Dyspnea and/or Thoracic pain without another obvious cause
  • Pulmonary embolism suspicion whatever the reason

You may not qualify if:

  • Age lower than 18
  • Patients hospitalized for more than 48h
  • Ongoing curative anticoagulant therapy for more than 48h before admission
  • Patients with thromboembolic disease diagnosed before the admission
  • Unavailability for follow-up (short life expectancy, no phone number…)
  • Patient refusing to be contacted by phone at 3 month
  • Patient refusing that medical data were collected

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Clinique Universitaire Saint-Luc

Brussels, Belgium

Location

UH Erasme

Brussels, Belgium

Location

UH Liège

Liège, Belgium

Location

Hospital of Agen

Agen, France

Location

UH Angers

Angers, France

Location

Hospital of Argenteuil

Argenteuil, France

Location

UH Clermont-Ferrand

Clermont-Ferrand, France

Location

Hospital of Le Mans

Le Mans, France

Location

UH Nantes

Nantes, France

Location

UH Poitiers

Poitiers, France

Location

UH Rennes

Rennes, France

Location

Hospital of Saint-Brieuc

Saint-Brieuc, France

Location

Related Publications (1)

  • Penaloza A, Soulie C, Moumneh T, Delmez Q, Ghuysen A, El Kouri D, Brice C, Marjanovic NS, Bouget J, Moustafa F, Trinh-Duc A, Le Gall C, Imsaad L, Chretien JM, Gable B, Girard P, Sanchez O, Schmidt J, Le Gal G, Meyer G, Delvau N, Roy PM. Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study. Lancet Haematol. 2017 Dec;4(12):e615-e621. doi: 10.1016/S2352-3026(17)30210-7. Epub 2017 Nov 14.

MeSH Terms

Conditions

Pulmonary EmbolismDyspneaChest Pain

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesRespiration DisordersSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsPainNeurologic Manifestations

Study Officials

  • Pierre-Marie ROY, MD-PhD

    UH Angers

    STUDY CHAIR
  • Andréa PENALOZA, MD-PhD

    Clinique Universitaire Saint-Luc, Bruxelles

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2015

First Posted

February 10, 2015

Study Start

May 1, 2015

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

September 22, 2016

Record last verified: 2016-09

Locations